The Indian Patent Office has rejected Viiv Healthcare's patent application for the HIV drug, dolutegravir, after nearly a decade of legal battles. This decision opens the market for generic versions, promoting affordable access to treatment and potentially reducing costs. The ruling addresses concerns over 'evergreening' practices in patent filings.
from Times of India https://ift.tt/tN7BrIF
Tuesday, October 15, 2024
Subscribe to:
Post Comments (Atom)
Hello, my name is Jack Sparrow. I'm a 50 year old self-employed Pirate from the Caribbean.
No comments:
Post a Comment